{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"\"Per International Myeloma Working Group (IMWG) Criteria: Complete Response (CR), Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow; Partial Response (PR), \\> 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \\>90% or to \\< 200 mg/24 h; Overall Response (OR) = CR + PR.\"","groups":[{"description":"Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Trametinib)"},{"description":"Patients who develop progressive disease on trametinib monotherapy or achieve less then a PR after 4 cycles of treatment will have the option to continue on trametinib with the addition of GSK2141795","id":"OG001","title":"Treatment (Trametinib, Akt Inhibitor GSK2141795)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Trametinib monotherapy arm not applicable for this outcome measure","reportingStatus":"POSTED","timeFrame":"Every 4 weeks until progression or death, whichever occurs first, an average of 9 months.","title":"ORR After the Addition of AKT Inhibitor GSK2141795 to Trametinib in Patients Who Have Developed Progressive Disease or Have Achieved Less Than a PR","type":"SECONDARY","unitOfMeasure":"Participants"}